T1	Participants 41 106	cetuximab-treated patients with advanced colorectal cancer (ACRC)
T2	Participants 304 337	advanced colorectal cancer (ACRC)
T3	Participants 773 810	five hundred and seventy-two patients
T4	Participants 437 473	cetuximab-treated patients with ACRC
